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Background. The aim of our work was to replicate, in a Southern European population, the association reported in Northern
populations between PTPRC locus and response to anti-tumor necrosis factor (anti-TNF) treatment in rheumatoid arthritis (RA).
We also looked at associations between five RA risk alleles and treatment response. Methods. We evaluated associations between
anti-TNF treatment responses assessed by DAS28 change and by EULAR response at six months in 383 Portuguese patients.
Univariate and multivariate linear and logistic regression analyses were performed. In a second step to confirm our findings, we
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pooled our population with 265 Spanish patients. Results. No association was found between PTPRC rs10919563 allele and anti-
TNF treatment response, neither in Portuguese modeling for several clinical variables nor in the overall population combining
Portuguese and Spanish patients. The minor allele for RA susceptibility, rs3761847 SNP in TRAF1/C5 region, was associated with
a poor response in linear and logistic univariate and multivariate regression analyses. No association was observed with the other
allellic variants. Results were confirmed in the pooled analysis. Conclusion. This study did not replicate the association between
PTPRC and the response to anti-TNF treatment in our Southern European population. We found that TRAF1/C5 risk RA variants
potentially influence anti-TNF treatment response.
1. Introduction
Rheumatoid arthritis (RA) is an inflammatory, chronic, and
disabling disease. Methotrexate is the most widely used
disease modifying antirheumatic drug (DMARD) in RA
treatment. However, for refractory and severe cases, anti-
tumor necrosis factor (anti-TNF) therapy has become a
cornerstone of RA treatment strategy [1]. These drugs have
revolutionized RA treatment and prognosis in the last 10–15
years. Nevertheless, only approximately one-third of patients
achieve remission and the other third will eventually fail to
respond [2]. In amultifactorial and polygenic disease like RA,
it is expected that response to treatmentmay be influenced by
genetic, clinical, and biological factors [3]. The identification
of predictors of response is of crucial importance to optimize
the cost-effective use of expensive medications, such as
anti-TNF therapy. Large registries collecting information on
sociodemographic characteristics, disease activity, functional
status, and treatments have allowed the study of clinical
predictors of response [4–7].
Genetic variants associatedwithRA susceptibility include
the HLA-DRB1 region containing shared epitope alleles (SE),
which is also associatedwith severity [8, 9]. Outside themajor
histocompatibility complex (MHC), PTPN22, TRAF1/C5,
and TNFAIP3 loci were the most consistently associated with
susceptibility and TRAF1/C5 region also with RA severity
[10, 11] and noncardiovascular mortality in some populations
[12].
In the nineties, studies performed to look at associations
between treatment response and the presence of SE indicated
that the response to disease modifying antirheumatic drugs
(DMARDs) such as methotrexate (MTX), in combination or
monotherapy [13], and more recently with leflunomide [14],
etanercept [15], and infliximab [16], was better in the presence
of SE.
In recent years, several studies of potential associations
between anti-TNF treatment response and polymorphisms
in the promoter region of the TNF gene (positions −308
and −238), and other related genes such as lymphotoxin-
𝛼 and TNF receptors, showed contradictory results [17–20].
With the increasing knowledge on RA pathophysiology and
genomewide studies demonstrating that loci related with
TNF signaling pathways such as theNF-kB signaling pathway
(TRAF1/C5, TNFAIP3, and REL) and other pathological pro-
cesses such as enhanced citrullination (PADI4) may increase
RA risk, it is compelling to explore how those loci could also
influence the anti-TNF response [21–28].
Cui et al., analyzing thirty-one risk allele variants, found
that the major allele (G) of the rs10919563 PTPRC locus,
which is a known predictor of RA risk, was associated with
an increased response to anti-TNF therapy, with stronger
association in seropositive patients (either anticitrullinated
peptides antibodies, ACPA, and/or rheumatoid factors (RF))
[29]. The authors did not find any association with treatment
response among the other thirty RA-associated risk alleles
studied. In that multicohort study, potential associations
between response and HLA-DRB1 were not assessed. One
study from BRAGGSS, UK, showed no association between
HLA-DRB1 and PTPN22 variants and response to anti-TNF
treatment [30]. However, another study from the UK con-
firmed the association between PTPRC variants and response
in the entire cohort, reporting no significance in the ACPA
positive group alone [31].
The challenge over the next years will be to identify the
RA stages in which genetic variants exert their maximum
influence and also to unveil their clinical significance and
usefulness as potential therapeutic targets or biomarkers [10].
In this study we aimed to replicate in a Southern Euro-
pean population the association between rs10919563 PTPRC
variants and the response to anti-TNF treatment found in
previous studies. We also aimed to test whether HLA-DRB1
and other five selected RA susceptibility genes may influ-
ence the response to anti-TNF treatment—that is, potential
associations between anti-TNF treatment response and risk
RA loci related with NF-kB signaling pathway (TRAF1/C5,
TNFAIP3, and REL), citrullination (PADI4), and the genetic
variants inside the MHC (HLA-DRB1∗04 high-resolution (4-
digit) genotyping) and outside the MHC (PTPN22 locus)
with the strongest association with RA risk. The analyses
were modeled adjusting for clinical variables that influenced
treatment response.
2. Material and Methods
2.1. Patients. Primary analyses were performed upon
Reuma.pt, the National Register for Rheumatic Diseases
from the Portuguese Society of Rheumatology (SPR)
established in 2008, which captures more than 90% of
patients treated with biological therapies managed in
rheumatology departments across Portugal [32]. The register
is linked to the Biobanco-IMM [33]. Blood samples were
collected from November 2010 up to May 2011 at six major
centers. Information on disease activity and treatments
has been collected by rheumatologists at every infusion for
intravenous drugs and every 3 months for subcutaneous
biologic therapies. The decision to initiate and maintain the
treatment was guided by the SPR’s recommendations [34].
RA patients fulfilling the American College of Rheumatology
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(ACR) 1987 revised criteria [35] were eligible for this study
whether they were treated with an anti-TNF agent as the first
biologic therapy, had a follow-up of at least six months, or
had a blood sample collected for DNA assessment. Patients
with self-reported non-Caucasian ancestry and those with
missing values for DAS28 at baseline or at six months were
excluded. Reuma.pt was approved by National Board of Data
Protection and Health National Directorate.
In a second step for confirming our findings, we pooled
our Portuguese sample with Spanish RA patients from the
RheumatologyDepartment ofVirgen de lasNieves (Granada,
Spain) and Reina Sofia (Córdoba, Spain) Hospitals, selected
with the criteria described above.
The study was conducted in accordance with the regu-
lations governing clinical trials such as the Declaration of
Helsinki and was approved by the Hospitals’ Ethics Commit-
tees. Patients signed an informed consent for research use of
their clinical data and blood samples.
2.2. DNA Extraction and Genotyping. DNA was extracted
from whole blood using the QIAamp DNA Blood Mini Kit
combined with the automated extraction device QIAcube
(QIAGEN, Hilden, Germany), according to the manufac-
turer’s instructions.
[PTPRC] rs10919563 (A/G) was previously reported in
association with anti-TNF treatment response [29, 31]. The
other five SNP markers were selected based on (1) relevance
for RA biologic NF-kB pathway, [6q23-TNFAIP3] rs10499194
(C/T), [REL] rs13031237 (G/T), and [TRAF1/C5] rs3761847
(A/G); (2) role on citrullination process, [PADI4] rs2240340
(C/T); and (3) strong association with RA risk, [PTPN22]
rs2476601 (A/G).HLA-DRB1∗04 high-resolution genotyping
was performed by PCR sequence-specific primers (SSP)
using Olerup SSP DRB1∗04 typing Kit (Olerup SSP AB) as
described in the manufacturers’ protocols.
Samples were run with Luminex xMAP system (Tepnel
Lifecodes). Allele call was obtained with Quicktype for
Lifematch 2.6 software. The samples were genotyped using
Taqman SNP genotyping assays (Applied Biosystems, Foster
City, USA) as described in the manufacturers’ protocols.
For purposes of quality control, 95% of sample threshold
and 95% genotyping success threshold were used. Exclusion
criteria also included a minor allele frequency <0.1 and
deviation from Hardy-Weinberg equilibrium. In the end,
HLA-DRB1∗04 and six allele variants were analyzed.
2.3. Statistical Analysis
2.3.1. Outcome Measures and Covariates. Our primary out-
come was the change in disease activity score in 28
joints including erythrocyte sedimentation rate measures
(DAS28ESR) between the drug start date and six months
of treatment (in our study, a positive variation means a
decrease in disease activity at six months in comparison with
baseline visit) [36]. Secondary outcomewas the proportion of
nonresponders versus good responders (excluding moderate
responders) defined by the EULAR response criteria at six
months [37]. Nonresponse was defined by an absolute change
in DAS28 ≤ 0.6 or a change in DAS28 between 0.6 and
1.2 with a DAS28 at six months >5.1. Good response was
defined as change in DAS28 of >1.2 and DAS28 at six months
≤3.2. In this study, nonresponse was the reference category,
with logistic regression analysis modeling the probability
of achieving good response. For both outcomes, covariates’
coefficient > 0 or odds ratio (OR) > 1 predicted favorable
response.
The predictors of interest were the minor allele variants
of PTPRC and the five SNPs described above as well as
the presence of SE (DRB1∗0401/04/05/08 and DRB1∗1001), as
previously described in the RA Portuguese population [8].
Covariates collected at drug start date (baseline visit)
were gender, age, age at diagnosis, disease duration, years
of education, smoking (ever/never), RF (positive/nega-
tive), ACPA (CCP2, positive/negative), extra-articular man-
ifestations (yes/no), concomitant therapy with corticos-
teroids (yes/no), any disease modifying antirheumatic drugs
(DMARDs) includingMTX (yes/no), DAS28, Health Assess-
ment Questionnaire (HAQ), and physician’s global assess-
ment of disease activity (PhGA). We tested the association
between these variables and change in DAS28 at six months
by univariate analyses. Then, we built a multivariate linear
model with the significant baseline clinical covariates (at a
𝑃 < 0.05). The variables that remained significant after
adjustment entered the multivariate model for each SNP.
In a second step, in order to confirm our results, we
pooled the Spanish population and looked at associations
between the SNPs and treatment response.
2.3.2. Primary Analysis. Each SNP was tested for an associa-
tion with the anti-TNF response, taking anti-TNF drugs as a
group. Univariate linear regression analyses for the primary
outcome and logistic regression for the secondary outcome
were performed, using additive models. Homozygotes for
major alleles were classified as 0, 1 for heterozygotes, and 2
for minor allele homozygotes. The response was also mod-
eled with multivariate models including significant baseline
clinical predictors for treatment response.
2.3.3. Secondary Analyses. For the loci that presented a sig-
nificant association with treatment response in the primary
analysis, we tested the same relationship by stratifying the
patients in ACPA positive and ACPA negative groups.
The study had >80% power to detect a change of >0.6 in
the DAS28 score (considered a clinically meaningful change
[37]) for allele frequencies > 0.1 and a type I error of <0.05.
There were no assumptions about the direction of effect
on treatment response. Results were considered significant
for a two sided𝑃 value <0.05. Analyses were performed using
SAS version 9.3 (SAS Institute, Cary, NC, USA).
3. Results
PTPRC, additional five SNP markers, and HLA-DRB1 geno-
typing were assessed in 416 Portuguese patients. Twenty-
seven reported a non-Caucasian ancestry and were excluded.
Six were excluded for absence of DAS28 at baseline or at six
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months, leaving 383 patients for analysis. Table 1 describes the
baseline demographic and clinical characteristics for the 383
RA Portuguese patients included in the study.
At six months, 119 (31.1%) patients were classified as
good responders, 175 (45.7%) asmoderate responders, and 89
(23.2%) as nonresponders according to the EULAR response
criteria [37].
Number of years completed at school, HAQ, and DAS28
at baseline were found to have a significant association with
treatment response at six months and were included in the
multivariate models (Table 2).
We did not find association between PTPRC rs10919563
and anti-TNF treatment response (Table 3).
Univariate analysis looking for association between the
other five risk alleles and anti-TNF treatment response
demonstrated a worse response for minor (G) allele,
rs3761847 SNP, in TRAF1/C5 region either measured by a
change inDAS28 at sixmonths (coefficient (coef.) −0.24; 95%
confidence interval (CI) −0.43, −0.06; 𝑃 value of 0.009) or by
the proportion of good responders versus nonresponders at
six months (OR 0.61; CI 0.41, 0.92; 𝑃 value of 0.018). After
adjusting for years of school completed, HAQ, and DAS28
at baseline, in two multivariate models, this association
remained significant for a 𝑃 value < 0.05 (Table 4). In the
univariate linear model, rs3761847 accounted for 1.75% of the
change in DAS28 at six months. The multivariate model with
the clinical covariates described above explained 23.9%of this
change. When rs3761847 was added to the clinical model, the
𝑅
2 increased to 25.4%.
There were no significant relationships between the other
SNP markers tested and response to therapy (Table 3). Simi-
larly, SEwas not associatedwith response to anti-TNF therapy
in our population (coef. 0.21, 𝑃 value 0.21; OR 1.24, CI 0.56,
2.71).
In a secondary stratified analysis, the relationship
between rs3761847 and treatment response in 278ACPAposi-
tive and 105 ACPAnegative patients was tested, but no associ-
ation was detected (ACPA positive group, coef. −0.16, 𝑃 value
0.09 and ACPA negative group, coef. −0.41, 𝑃 value 0.04).
We replicated these findings pooling 265 Spanish RA
patients and testing the association between the risk alleles
and anti-TNF treatment response (results not shown).
4. Discussion
Our study did not replicate the association previously pub-
lished between PTPRC rs10919563 variant and the response
to anti-TNF therapy in patients with RA. The analyses
suggest that in our Southern European population, theminor
(G) allele rs3761847 in the TRAF1/C5 locus might have an
association with poor response to anti-TNF treatment at
six months. These results were consistent using either the
absolute change in DAS28 or the proportion of good/non-
responders as outcomes in univariate and multivariate mod-
els adjusted for clinical predictors of response. The other
four RA susceptibility loci tested and theHLADRB1 were not
associated with anti-TNF response.
Table 1: Baseline demographic and clinical characteristics of the 383






Age (years) 52.5 (12.2)
Disease duration (years) 10.7 (8.9)
Female 343 (89.5)
Rheumatoid factor 290 (75.7)
ACPA 278 (72.6)
Extra-articular manifestations 91 (23.7)
Smoking-ever (𝑛 = 367) 71 (19.3)
Education (years) 7.1 (4.6)
DMARDs (𝑛 = 377) 346 (91.8)
MTX (𝑛 = 377) 310 (82.2)
Corticosteroids (𝑛 = 377) 277 (73.5)
DAS28 ESR 5.77 (1.1)
Physician global assessment (mm) 56.1 (16.5)
Health Assessment Questionnaire 1.45 (0.58)
Values shown are means (SD) or 𝑛 (%).
TNF: tumor necrosis factor; ACPA: anticitrullinated peptides antibodies;
DMARDs: disease modifying antirheumatic drugs; MTX: methotrexate;
DAS: disease activity score; ESR: erythrocyte sedimentation rate.
Table 2: Multivariate model of baseline demographic and clinical
variables as predictors of response to anti-TNF treatment at 6
months.
Baseline variables Coefficient (𝑃 value)
Age (years) −0.01 (0.25)
Disease duration (years) 0.01 (0.24)
Female gender −0.01 (0.95)
ACPA (positive) −0.07 (0.64)
Smoking (ever) −0.06 (0.72)
Higher education (years) 0.03 (0.03)∗
Corticosteroids (yes) −0.16 (0.26)
DMARDs (yes) 0.05 (0.83)
Extra-artic. manif. (yes) 0.10 (0.49)
HAQ −0.40 (0.002)∗




The probability of response to anti-tumor necrosis factor therapy at 6months
was modeled in a multivariate linear regression analysis.
The change in disease activity score assessing 28 joints between the baseline
visit and the visit after 6 months of therapy was the continuous outcome.
ACPA: anticitrullinated peptides antibodies; DMARDs: disease modifying
antirheumatic drugs; Extra-artic. manif.: extra-articular manifestations;
HAQ: Health Assessment Questionnaire; PhGA: physician global assess-
ment; DAS: disease activity score.
In 2007, TRAF1/C5 was identified as a risk locus for RA
by Plenge and colleagues in a GWAS [21] and by Kurreeman
et al. in a candidate gene approach [38]. More recently, it
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was shown to be a marker of disease severity [10, 11] and in
one study of noncardiovascular mortality [12]. No previous
studies have reported the association with response to anti-
TNF therapy. Due to a high level of linkage disequilibrium
between the genes encoding TNF receptor associated factor
1 and complement component 5, it is currently not possible
to assure which of these two genes at 9q33.2 encloses the
causal variant. Both are possible candidates. The protein,
TNF receptor-associated factor 1 (TRAF1), is a member of
the TNF receptor (TNFR) associated factor (TRAF) protein
family and is encoded by the TRAF gene. TRAF proteins
associate with and mediate the signal transduction from
various receptors of the TNFR superfamily. TRAF1 and
TRAF2 form a heterodimeric complex, which is required
for TNF mediated activation of MAPK8/JNK and NF-kB.
The protein complex interacts with inhibitor-of-apoptosis
proteins and mediates the antiapoptotic signals from TNF
receptors. TRAF 1 is a negative regulator of TNF receptor
and Toll-like receptor signaling and may contribute to the
proliferation of T cells. rs3761847 is located at the upstream
of TRAF1 and the downstream of the complement fraction
C5 [39]. The clinical and biologic data for C5 are equally
relevant.The complement pathway has been implicated in the
pathogenesis of rheumatoid arthritis for more than 30 years.
C5 cleavage generates the proinflammatory anaphylatoxin
C5a, as well as C5b, which initiates the generation of the
membrane-attack complex. C5-deficient mice are resistant to
inflammatory arthritis in models with a dominant humoral
component [21, 40]. It is compelling to hypothesize that
this variant or other causative variants at this locus may
influence the function or expression levels of TRAF1 and/or
C5, affecting RA susceptibility, severity, and anti-TNF treat-
ment response. Functional studies are warranted to confirm
these hypotheses. Nevertheless, our result could be that false
positive and studies with other populations are required to
confirm the replication of these findings.
We did not find any significant associations between
response to treatment and the presence of SE, neither with
the other four RA risk allele variants related with NF-kB
signaling pathway nor with citrullination, chosen for its high
association with RA susceptibility. We were also not able
to replicate the previously reported PTPRC association with
treatment response in our Southern European population.
Plant et al. reported a 𝑃 value of 0.04 for PTPRC association
with anti-TNF treatment response and no significance for
the ACPA positive patients in the stratified analysis. This
result was strengthenedwith ameta-analysis combining their
data with the Cui et al. study [29]. Although our sample size
was large enough to detect allele variants association with
response with a power > 80% for minor allele frequency
(MAF) > 0.1, PTPRC showed a MAF of 0.11 which might
have made difficult the detection of association.The different
genetic background of our population could also account for
the lack of replication. In a recent study, we and two Japanese
groups also failed to replicate the results found in Northern
European populations [41].
We are far from understanding the genetic mecha-
nisms that underlie treatment response in patients with RA,
as demonstrated by the large proportion of the variance
explained by clinical factors compared to that explained by a
single SNP.The ultimate goal for genetic, laboratory, and clin-
ical predictors of treatment response studies is personalizing
treatment and medicine practice by identifying biomarkers
and specific phenotypes clinically useful for improving the
therapeutic strategy. The identification of individual predic-
tors may contribute to building complex algorithms aimed at
improving the prediction of a better/worse response to anti-
TNF drugs and other classes of biologic therapies.
5. Conclusions
We were not able to replicate the previously reported PTPRC
rs10919563 association with treatment response in our South-
ern European RA population.
The minor (G) allele of rs3761847 in the TRAF1/C5
locus, which is a susceptibility factor for RA related to TNF
signaling, was associated with a poor response to anti-TNF
treatment at six months, using either the absolute change
in DAS28 or the proportion of good responders and non-
responders as outcomes. This association was also observed
after adjustment in amultivariatemodel with baseline clinical
predictors of response.
We did not find any significant associations between
response to treatment and the presence of SE, neither with
the other four RA risk allele variants related with NF-kB
signaling pathway nor with citrullination, chosen for its high
association with susceptibility.
Additional studies in other populations are necessary to
confirm the relevance of these findings.
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